{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T05:28:51Z","timestamp":1782019731190,"version":"3.54.5"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,10]],"date-time":"2014-06-10T00:00:00Z","timestamp":1402358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.ijid.2014.04.030","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T16:24:25Z","timestamp":1402935865000},"page":"165-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment"],"prefix":"10.1016","volume":"25","author":[{"given":"Hung","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shin","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chi","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2014.04.030_bib0005","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3109\/10428194.2012.656626","article-title":"Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications","volume":"53","author":"Rodriguez","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijid.2014.04.030_bib0010","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","article-title":"Immunosuppression and atypical infections in CML patients treated with dasatinib at 140mg daily","volume":"39","author":"Sillaber","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ijid.2014.04.030_bib0015","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2008-02-138701","article-title":"Dasatinib suppresses in vitro natural killer cell cytotoxicity","volume":"111","author":"Blake","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2014.04.030_bib0020","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/leu.2011.135","article-title":"Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation","volume":"25","author":"Kreutzman","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.ijid.2014.04.030_bib0025","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/leu.2012.348","article-title":"Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy","volume":"27","author":"Mustjoki","year":"2013","journal-title":"Leukemia"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971214015276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971214015276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T10:53:50Z","timestamp":1538564030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971214015276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":5,"alternative-id":["S1201971214015276"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2014.04.030","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2014.04.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}